Compare Dolby Laboratories, Inc. (DLB) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Stryker Corporation — how do they compare? Dolby Laboratories, Inc. trades at $58.9 (market cap $5.47B), while Stryker Corporation trades at $276.9 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 19.4× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.46%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Stryker Corporation for 20 Days on average.
| DLB | SYK | |
|---|---|---|
Market Cap | $5.47B | $106.24B |
Volume | 1,058,284 | 2,982,001 |
Sector | Technology | Health |
52-Week High | $70.09 | $388.35 |
52-Week Low | $48.51 | $269.75 |
Typical Hold Time | 98 Days | 20 Days |
Enterprise Value | $4.85B | $117.70B |
Dividend Yield | 2.46% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals. The company maintains strong profitability with 87.61% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten. Cash flow improved significantly in 2025 with $472M operating cash flow.
DLB presents a mixed outlook with strong fundamentals but technical weakness. The 47% upside to $90.33 consensus target offers potential, though near-term execution risks and licensing volatility remain concerns. Revenue stability around $1.3B and premium valuation metrics require continued innovation execution to justify current multiples.
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
